Steven W Elmore
Overview
Explore the profile of Steven W Elmore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
6077
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Ackler S, Xiao Y, Mitten M, Foster K, Oleksijew A, Refici M, et al.
Mol Cancer Ther
. 2008 Oct;
7(10):3265-74.
PMID: 18852130
ABT-263 is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x(L), and Bcl-w, which is currently in phase I clinical trials. Previous work has shown that...
22.
Park C, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, et al.
J Med Chem
. 2008 Oct;
51(21):6902-15.
PMID: 18841882
Overexpression of prosurvival proteins such as Bcl-2 and Bcl-X L has been correlated with tumorigenesis and resistance to chemotherapy, and thus, the development of antagonists of these proteins may provide...
23.
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models
Shoemaker A, Mitten M, Adickes J, Ackler S, Refici M, Ferguson D, et al.
Clin Cancer Res
. 2008 Jun;
14(11):3268-77.
PMID: 18519752
Purpose: The purpose of this study was to characterize the activity of the Bcl-2 protein family inhibitor ABT-263 in a panel of small cell lung cancer (SCLC) xenograft models. Experimental...
24.
Tse C, Shoemaker A, Adickes J, Anderson M, Chen J, Jin S, et al.
Cancer Res
. 2008 May;
68(9):3421-8.
PMID: 18451170
Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is commonly associated with tumor maintenance, progression, and chemoresistance. We previously reported the discovery of ABT-737, a potent, small-molecule...
25.
Huth J, Park C, Petros A, Kunzer A, Wendt M, Wang X, et al.
Chem Biol Drug Des
. 2007 Jul;
70(1):1-12.
PMID: 17630989
The molecular chaperone HSP90 has been shown to facilitate cancer cell survival by stabilizing key proteins responsible for a malignant phenotype. We report here the results of parallel fragment-based drug...
26.
Wendt M, Sun C, Kunzer A, Sauer D, Sarris K, Hoff E, et al.
Bioorg Med Chem Lett
. 2007 Mar;
17(11):3122-9.
PMID: 17391963
Survivin is one of the most tumor-specific genes in the human genome and is an attractive target for cancer therapy. However, small-molecule ligands for survivin have not yet been described....
27.
Bruncko M, Oost T, Belli B, Ding H, Joseph M, Kunzer A, et al.
J Med Chem
. 2007 Jan;
50(4):641-62.
PMID: 17256834
Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy. Inhibition of these prosurvival...
28.
Park C, Oie T, Petros A, Zhang H, Nimmer P, Henry R, et al.
J Am Chem Soc
. 2006 Dec;
128(50):16206-12.
PMID: 17165773
One of the primary objectives in the design of protein inhibitors is to shape the three-dimensional structures of small molecules to be complementary to the binding site of a target...
29.
Shoemaker A, Oleksijew A, Bauch J, Belli B, Borre T, Bruncko M, et al.
Cancer Res
. 2006 Sep;
66(17):8731-9.
PMID: 16951189
Inhibition of the prosurvival members of the Bcl-2 family of proteins represents an attractive strategy for the treatment of cancer. We have previously reported the activity of ABT-737, a potent...
30.
Wendt M, Shen W, Kunzer A, McClellan W, Bruncko M, Oost T, et al.
J Med Chem
. 2006 Feb;
49(3):1165-81.
PMID: 16451081
Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X(L) function, is described. Lead compounds generated by NMR screening and directed parallel synthesis displayed sub-microM binding but...